Clinical Research Directory

Inclusion Criteria: 1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study. 3. Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label. 4. Male or female, aged ≥ 19 years at the time of signing the informed consent. Exclusion Criteria: 1. Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study. 2. Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice). 3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.